Method of cardioprotection
AssigneeRace Oncology Ltd.
InventorsDaniel TILLETT, Doan Thi Minh NGO, Aaron Leonid SVERDLOV
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods comprising administering to the subject an effective amount of a cardioprotective agent comprising bisantrene or a derivative thereof, or a pharmaceutically acceptable salt of bisantrene or derivative thereof.
Claims29
A method for preventing or reducing drug-induced cardiotoxicity in a subject caused by a cardiotoxic agent, the method comprising administering to the subject an effective amount of a cardioprotective agent comprising bisantrene or a derivative thereof, or a pharmaceutically acceptable salt of bisantrene or derivative thereof.
A pharmaceutical composition comprising a cardioprotective agent comprising bisantrene or a derivative thereof, or a pharmaceutically acceptable salt of bisantrene or derivative thereof, and a cardiotoxic therapeutic agent.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A kit for preventing or reducing drug-induced cardiotoxicity in a subject caused by a cardiotoxic therapeutic agent, said kit comprising a cardioprotective agent comprising bisantrene or a derivative thereof, or a pharmaceutically acceptable salt of bisantrene or derivative thereof, and said cardiotoxic therapeutic agent.
Dependencies are inferred from the claim text.